Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its Lyme disease vaccine candidate VLA15.
Fast Track designation is granted by the FDA to products that are under development for serious conditions and have the potential to fulfill an unmet medical need. It is designed to facilitate the clinical development and expedite the review of new drugs and vaccines with the intention to accelerate the availability of promising products on the market1.
Thomas Lingelbach, President and CEO of Valneva commented, “Lyme disease affects an increasing number of people each year, many of whom have to live with long-term sequelae that are not only extremely difficult to treat but also represent a heavy health economic burden. We feel privileged to advance the only active clinical stage Lyme vaccine candidate to date and are looking forward to working closely with the FDA and other authorities to facilitate the development towards approval.”
Valneva recently completed subject enrollment for the ongoing Phase I study of its Lyme disease vaccine candidate. The study is being conducted at three sites – two in the U.S. and one in Europe (Belgium) – combining approximately 180 subjects aged between 18 and 40 years. The primary objective of the observer-blind, partially randomized, dose escalation study is to evaluate the vaccine candidate´s safety and tolerability profile at different dose levels and formulations.
Immunogenicity, measured by observing IgG antibodies2 against the six most prevalent serotypes of Lyme borreliosis in the US and Europe present in the vaccine, will also be monitored for different dose groups and formulations at different time-points.
Given the steady increase in the incidence of the disease and its spread to new territories, Valneva is committed to accelerate the development of VLA15 as a novel prevention against such a high-priority medical need. As such, the company plans to initiate Phase II as early as the first quarter of 2018.
Pre-clinical data showed that Valneva’s vaccine candidate had the potential to provide protection against the majority of Borrelia species pathogenic for humans3.
About Lyme disease
Lyme disease (LD), also known as Lyme borreliosis, is an infectious disease caused by Borrelia bacteria which are transmitted to humans by infected ticks. Early symptoms of Lyme disease (such as a gradually expanding erythematous rash called Erythema migrans or more unspecific symptoms like fatigue, fever, headache, mild stiff neck, arthralgia or myalgia) are often overlooked or misinterpreted. When treatment for LD is delayed or inadequate, infection with Borrelia can lead to serious complications involving the joints, heart and central nervous system. Each year, an estimated 300,000 US citizens4and 85,000 Europeans5develop Lyme disease. It was diagnosed as a separate condition for the first time in 1975 in Old Lyme, Connecticut.
VLA15 is a new hexavalent, protein subunit-based vaccine candidate targeting the Outer Surface Protein A (OspA) of Borrelia, the most dominant protein expressed by the bacteria when present in a tick. By targeting the most prevalent serotypes of Borrelia and blocking the transmission of these Lyme-causing bacteria from the tick to the host, the vaccine has the potential to protect from Borrelia infection in the U.S., Europe, and potentially worldwide. The target indication for Valneva’s vaccine candidate is the active prophylactic immunization against Lyme disease in children and adults. The global market for a vaccine against Lyme disease is estimated at approximately €700 - €800 million annually6.
About Valneva SE
Valneva is a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT®indicated for the prevention of Japanese encephalitis and DUKORAL®indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66®vaccine production cell line, IC31®adjuvant).
Valneva shares are tradable on Euronext-Paris, the Vienna stock exchange and Deutsche Börse’s electronic platform Xetra®. The Company has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com.
Head of Investor Relations & Corporate Communications
Tel: +02 28-07-14-19
Mobil: +33 (0)6 4516 7099
Corporate Communications Specialist
Tel: +43 (0)1 206 20-1149